Colección SciELO Chile

Departamento Gestión de Conocimiento, Monitoreo y Prospección
Consultas o comentarios: productividad@anid.cl
Búsqueda Publicación
Búsqueda por Tema Título, Abstract y Keywords



Value of intraventricular dyssynchrony assessment by gated-SPECT myocardial perfusion imaging in the management of heart failure patients undergoing cardiac resynchronization therapy (VISION-CRT)
Indexado
WoS WOS:000624078000009
Scopus SCOPUS_ID:85060716709
DOI 10.1007/S12350-018-01589-5
Año 2021
Tipo artículo de investigación

Citas Totales

Autores Afiliación Chile

Instituciones Chile

% Participación
Internacional

Autores
Afiliación Extranjera

Instituciones
Extranjeras


Abstract



Background: Placing the left ventricular (LV) lead in a viable segment with the latest mechanical activation (vSOLA) may be associated with optimal cardiac resynchronization therapy (CRT) response. We assessed the role of gated SPECT myocardial perfusion imaging (gSPECT MPI) in predicting clinical outcomes at 6 months in patients submitted to CRT. Methods: Ten centers from 8 countries enrolled 195 consecutive patients. All underwent gSPECT MPI before and 6 months after CRT. The procedure was performed as per current guidelines, the operators being unaware of gSPECT MPI results. Regional LV dyssynchrony (Phase SD) and vSOLA were automatically determined using a 17 segment model. The lead was considered on-target if placed in vSOLA. The primary outcome was improvement in ≥1 of the following: ≥1 NYHA class, left ventricular ejection fraction (LVEF) by ≥5%, reduction in end-systolic volume by ≥15%, and ≥5 points in Minnesota Living With Heart Failure Questionnaire (MLHFQ). Results: Sixteen patients died before the follow-up gSPECT MPI. The primary outcome occurred in 152 out of 179 (84.9%) cases. Mean change in LV phase standard deviation (PSD) at 6 months was 10.5°. Baseline dyssynchrony was not associated with the primary outcome. However, change in LV PSD from baseline was associated with the primary outcome (OR 1.04, 95% CI 1.01-1.07, P = .007). Change in LV PSD had an AUC of 0.78 (0.66-0.90) for the primary outcome. Improvement in LV PSD of 4° resulted in the highest positive likelihood ratio of 7.4 for a favorable outcome. In 23% of the patients, the CRT lead was placed in the vSOLA, and in 42% in either this segment or in a segment within 10° of it. On-target lead placement was not significantly associated with the primary outcome (OR 1.53, 95% CI 0.71-3.28). Conclusion: LV dyssynchrony improvement by gSPECT MPI, but not on-target lead placement, predicts clinical outcomes in patients undergoing CRT.

Métricas Externas



PlumX Altmetric Dimensions

Muestra métricas de impacto externas asociadas a la publicación. Para mayor detalle:

Disciplinas de Investigación



WOS
Cardiac & Cardiovascular Systems
Radiology, Nuclear Medicine & Medical Imaging
Cardiac & Cardiovascular System
Scopus
Sin Disciplinas
SciELO
Sin Disciplinas

Muestra la distribución de disciplinas para esta publicación.

Publicaciones WoS (Ediciones: ISSHP, ISTP, AHCI, SSCI, SCI), Scopus, SciELO Chile.

Colaboración Institucional



Muestra la distribución de colaboración, tanto nacional como extranjera, generada en esta publicación.


Autores - Afiliación



Ord. Autor Género Institución - País
1 Peix, A. Mujer Institute of Cardiology - Cuba
INST CARDIOL - Cuba
2 SOTOMAYOR-PROSCHLE, VIVIANA Hombre All India Institute of Medical Sciences, New Delhi - India
All India Inst Med Sci - India
3 MASSARDO-VEGA, LUCÍA TERESA Mujer Hospital Clínico de la Universidad de Chile - Chile
Hosp Clin Univ Chile - Chile
Hospital Clínico Universidad de Chile - Chile
4 Kalaivani, Mani Hombre All India Institute of Medical Sciences, New Delhi - India
All India Inst Med Sci - India
5 Patel, Chetan - All India Institute of Medical Sciences, New Delhi - India
All India Inst Med Sci - India
6 Pabon, Luz M. Mujer Fundación Valle del Lili - Colombia
Fdn Valle del Lili - Colombia
7 Jiménez-Heffernan, Amelia Mujer Clinica de Coloproctologia Hospital Juan Romon Jimenez - España
Hosp Juan Ramon Jimenez - España
7 Jimenez-Heffernan, Amelia Mujer Hosp Juan Ramon Jimenez - España
8 Puri, Raman Hombre Instituto Nacional de Cardiología Ignacio Chávez - México
INST NACL CARDIOL IGNACIO CHAVEZ - México
9 Butt, Sadaf Mujer Pakistan Atomic Energy Commission - Pakistán
Oncol & Radiotherapy Inst NORI - Pakistán
10 Kumar, Alka Mujer Dr. BL Kapur Memorial Hospital - India
Dr BL Kapur Mem Hosp - India
Dr. B L Kapur Memorial Hospital - India
11 Marin, Victor Hombre Fundación Cardioinfantil - Instituto de Cardiología - Colombia
Fdn CardioInfantil - Colombia
12 Mesquita, Claudio Tinoco Hombre Hospital Universitario Antônio Pedro - Brasil
Hosp Univ Antonio Pedro - Brasil
13 Morozova, O. Mujer International Atomic Energy Agency, Vienna - Austria
IAEA - Austria
14 PAEZ-GUTIERREZ, DIANA Mujer International Atomic Energy Agency, Vienna - Austria
IAEA - Austria
15 Garcia, Ernest V. Hombre Emory University - Estados Unidos
EMORY UNIV - Estados Unidos

Muestra la afiliación y género (detectado) para los co-autores de la publicación.

Origen de Citas Identificadas



Muestra la distribución de países cuyos autores citan a la publicación consultada.

Citas identificadas: Las citas provienen de documentos incluidos en la base de datos de DATACIENCIA

Citas Identificadas: 6.06 %
Citas No-identificadas: 93.94 %

Muestra la distribución de instituciones nacionales o extranjeras cuyos autores citan a la publicación consultada.

Citas identificadas: Las citas provienen de documentos incluidos en la base de datos de DATACIENCIA

Citas Identificadas: 6.06 %
Citas No-identificadas: 93.94 %

Financiamiento



Fuente
Sin Información

Muestra la fuente de financiamiento declarada en la publicación.

Agradecimientos



Agradecimiento
We are grateful to Adrienne Hunter, Ph.D., for her dedication in reviewing the manuscript. Dr Garcia receives royalties from the sale of the Emory Cardiac Toolbox used in this research. The terms of this arrangement have been reviewed and approved by Emory University in accordance with its COI practice. He is also a consultant for Syntermed Inc and GE Healthcare. There are no other relationships with industry.

Muestra la fuente de financiamiento declarada en la publicación.